IDEMIA Trials Biometric Verification Program with Royal Caribbean Cruises Ltd. and U.S. Customs and Border Protection
IDEMIA, the global leader in trusted identities for an increasingly digital world and the country’s preeminent identity-related service provider, and Royal Caribbean Cruises Ltd. (RCL) jointly announced today they have completed a trial with U.S. Customs and Border Protection (CBP) using facial recognition to validate passengers’ identities for entry and re-entry of cruise ships to further secure and expedite passenger processing at U.S. sea-ports of entry.
A “Sea Re-entry” trial, conducted at Cape Liberty Cruise Port in New Jersey, utilized IDEMIA’s facial capture and recognition solution to confirm the facial identities of individuals disembarking Royal Caribbean ships with the facial identities of ticketed passengers who boarded the ship at the start of a cruise. The trial demonstrated high quality/high speed facial matching with large passenger populations, expedited Customs egress and confirmation that individuals embarking the ship are the same as those disembarking. Surveys of disembarking passengers showed high degrees of satisfaction regarding speed of clearing customs and intuitive engagement with the facial camera.
RCL, IDEMIA and CBP jointly viewed the Sea Re-entry trials as a strong example of public-private partnership. “IDEMIA is at the forefront of the ‘Passenger Transformation’”, said Bob Eckel, President of IDEMIA North America. “Passengers need to move safely, but also fast and conveniently through the border processes. The biometric solutions we are testing with RCL and CBP allow us to demonstrate the important technology that can be used in border management applications today in an efficient and safe manner. Facial recognition in particular is a non-intrusive way to easily and securely facilitate U.S. and non-U.S. citizens entering and exiting the country, an initiative important to the Federal government.”
Captain Thomas Hinderhofer of RCL and Director of Cape Liberty Port Operations states: “Royal Caribbean’s commitment to providing our guests a pleasurable experience includes making the final step of clearing customs fast, secure and frictionless. The trial exceeded our expectations in terms of being able to quickly process passengers re-entering the country while at the same time addressing key border management requirements.”
# # #
About IDEMIA
OT-Morpho is now IDEMIA, the global leader in
trusted identities for an increasingly digital world, with the ambition
to empower citizens and consumers alike to interact, pay, connect,
travel and vote in ways that are now possible in a connected environment.
Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, we reinvent the way we think, produce, use and protect this asset, whether for individuals or for objects. We ensure privacy and trust as well as guarantee secure, authenticated and verifiable transactions for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.
With close to €3bn in revenues, IDEMIA is the result of the coming together of OT (Oberthur Technologies) and Safran Identity & Security (Morpho). This new company counts 14,000 employees of more than 80 nationalities and serves clients in 180 countries.
For more information, visit www.idemia.com / Follow @IdemiaGroup on Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171114006151/en/
Contact information
Press contacts
IDEMIA
Elizabeth MARSHALL, T +
978-215-2513
elizabeth.marshall@us.idemia.com
or
Olmstead
Williams
Trish MCCALL, M + 805-390-3279
tmccall@olmsteadwilliams.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
You Up? Grindr’s “Right Now” Goes Global30.5.2025 16:00:00 EEST | Press release
Grindr, the Global Gayborhood in Your Pocket™ with more than 14.6M average monthly active users, today announced the global launch of Right Now, their newest intent-based feature designed to instantly connect people looking for immediate encounters. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250530651954/en/ Grindr's Right Now feature. Right Now is a real-time feed—separate from the app’s main grid that displays profiles—where Grindr users can post text and share photos displayed for one hour, letting other like-minded users know exactly what they’re looking for. “Right Now empowers our users to find exactly what they want, when they want it – without the guesswork,” said AJ Balance, Chief Product Officer at Grindr. “We built this intention-based feature based on feedback from our community so they can connect with like-minded people without wasting time on mismatched expectations. The response to our initial March launc
CAR T Vision Coalition Launches with Ambitious Goal to Double Patients Treated with the Curative Potential of CAR T-cell Therapy by 203030.5.2025 15:00:00 EEST | Press release
Today an international coalition announces the launch of CAR T Vision to unite stakeholders around the shared ambition that every eligible patient should have the opportunity for cure with CAR T-cell therapy. By 2030, the aim is to double the proportion of eligible patients treated with CAR T-cell therapy. As outlined in the new roadmap report, the coalition will work to address access challenges and drive meaningful change in the CAR T-cell therapy healthcare ecosystem with a focus on three critical priorities: increasing awareness and understanding of CAR T-cell therapy; expanding resources and capacity to deliver CAR T-cell therapy; and developing sustainable and innovative financing approaches to manage the costs of treatment and care. “Despite CAR T-cell therapy being available in the United States for nearly seven years in large B-cell lymphoma, only approximately two out of 10 eligible patients with some advanced blood cancers ever receive CAR T-cell therapy,” said Miguel Perale
Indian Educationist Dr. Achyuta Samanta Recognised With Research Institute in His Name at CUNY, USA30.5.2025 12:17:00 EEST | Press release
In a noteworthy development underscoring growing academic collaboration between India and the United States, the City University of New York (CUNY) has launched a dedicated research platform—the Achyuta Samanta India Initiative of the CUNY CREST Institute (ASIICCI). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529012005/en/ Dr. Milton Santiago, President of Bronx Community College, and Dr. Achyuta Samanta, Founder of KIIT & KISS, jointly inaugurate the Achyuta Samanta India Initiative of CUNY CREST Institute (ASIICCI) with a ribbon-cutting ceremony in New York. Named after Dr. Achyuta Samanta, a noted Indian educationist and social worker, the initiative focuses on academic research in Indian social and educational sectors, with a particular lens on Odisha. This marks one of the rare instances of a living Indian being honoured with such a naming in an American public university system. Dr. Samanta, who hails from Odisha
FDA Grants De Novo Clearance for Reflow Medical's Spur ® Peripheral Retrievable Stent System30.5.2025 07:08:00 EEST | Press release
Reflow Medical, Inc., a leading developer of innovative medical devices focused on complex cardiovascular disease, announced that the U.S. Food and Drug Administration (FDA) has granted De Novo clearance for the company’s Spur Peripheral Retrievable Stent System, a unique clinical solution for the treatment of de novo or restenotic lesions following predilatation in patients with infrapopliteal arterial disease. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250529610368/en/ The first and only retrievable stent system that features a self-expanding stent with an integrated dilatation balloon catheter on an over-the-wire system. It is designed for controlled lesion penetration and treatment through a series of radially expandable spikes. Known as Retrievable Scaffold Therapy (RST), the spikes on the Spur Stent penetrate the lesion to increase the acute luminal diameter and modify the lesion morphology to change vessel complia
Black Forest Labs Launches FLUX.1 Kontext, a Breakthrough in Context-aware Image Generation and Editing29.5.2025 23:27:00 EEST | Press release
Black Forest Labs, Europe’s fast-rising frontier AI research lab, announced today the release of FLUX.1 Kontext, a new suite of image generation models that introduce powerful in-context generating and editing capabilities. Kontext enables users to generate, retouch, and iteratively refine images from both text and visual inputs, without the need for finetuning or complex editing workflows. FLUX.1 Kontext is designed for creators, developers, and enterprises seeking precision and creative control. The model can understand and extract visual concepts from images, maintain stylistic and character consistency across multiple scenes, and apply localized edits with exceptional fidelity. This enables seamless visual storytelling, fast ideation, and highly targeted content generation, all at inference speeds up to 8x faster than leading alternatives. "FLUX.1 Kontext represents a fundamental shift from traditional editing approaches by unifying image generation and editing in a single flow mat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom